KONFIDENT Phase 3 Trial Design for Sebetralstat (KVD900), a Novel Investigational Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angloedema Attacks
Lumry WR, Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA, Audhya PK, Smith MD, Yea CM, Riedl MA, Maurer M
EAC 2022